429 related articles for article (PubMed ID: 32721111)
1. Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute.
Lee KCE; Mui WH; Chan W; Wong CSF; Chu SKP
Cancer Rep (Hoboken); 2019 Aug; 2(4):e1170. PubMed ID: 32721111
[TBL] [Abstract][Full Text] [Related]
2. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
[TBL] [Abstract][Full Text] [Related]
4. Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
Rose TL; Harrison MR; Deal AM; Ramalingam S; Whang YE; Brower B; Dunn M; Osterman CK; Heiling HM; Bjurlin MA; Smith AB; Nielsen ME; Tan HJ; Wallen E; Woods ME; George D; Zhang T; Drier A; Kim WY; Milowsky MI
J Clin Oncol; 2021 Oct; 39(28):3140-3148. PubMed ID: 34428076
[TBL] [Abstract][Full Text] [Related]
5. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
Ravi P; Pond GR; Diamantopoulos LN; Su C; Alva A; Jain RK; Skelton WP; Gupta S; Tward JD; Olson KM; Singh P; Grunewald CM; Niegisch G; Lee JL; Gallina A; Bandini M; Necchi A; Mossanen M; McGregor BA; Curran C; Grivas P; Sonpavde GP
BJU Int; 2021 Nov; 128(5):607-614. PubMed ID: 33909949
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study.
Okabe K; Shindo T; Maehana T; Nishiyama N; Hashimoto K; Itoh N; Takahashi A; Taguchi K; Tachiki H; Tanaka T; Masumori N
Jpn J Clin Oncol; 2018 Oct; 48(10):934-941. PubMed ID: 30169681
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
Meleis L; Moore R; Inman BA; Harrison MR
J Oncol Pharm Pract; 2020 Mar; 26(2):330-337. PubMed ID: 31081469
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
[TBL] [Abstract][Full Text] [Related]
9. [Impact of neoadjuvant chemotherapy on the peri-operative morbidity of radical cystectomy for muscle invasive bladder cancer].
Michel C; Vordos D; Dumont C; Basset V; Meyer F; Gaudez F; Meria P; Cortesse A; Mongiat-Artus P; de la Taille A; Culine S; Desgrandchamps F; Masson-Lecomte A
Prog Urol; 2018 Sep; 28(10):495-501. PubMed ID: 29997033
[TBL] [Abstract][Full Text] [Related]
10. The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Murasawa H; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Iwabuchi I; Ogasawara M; Kawaguchi T
Int J Clin Oncol; 2017 Feb; 22(1):159-165. PubMed ID: 27534866
[TBL] [Abstract][Full Text] [Related]
11. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.
Iyer G; Balar AV; Milowsky MI; Bochner BH; Dalbagni G; Donat SM; Herr HW; Huang WC; Taneja SS; Woods M; Ostrovnaya I; Al-Ahmadie H; Arcila ME; Riches JC; Meier A; Bourque C; Shady M; Won H; Rose TL; Kim WY; Kania BE; Boyd ME; Cipolla CK; Regazzi AM; Delbeau D; McCoy AS; Vargas HA; Berger MF; Solit DB; Rosenberg JE; Bajorin DF
J Clin Oncol; 2018 Jul; 36(19):1949-1956. PubMed ID: 29742009
[TBL] [Abstract][Full Text] [Related]
12. Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer.
Matsubara N; Mukai H; Naito Y; Nezu M; Itoh K
Asia Pac J Clin Oncol; 2013 Dec; 9(4):310-7. PubMed ID: 23127231
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer.
Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y
Med Oncol; 2014 May; 31(5):949. PubMed ID: 24700028
[TBL] [Abstract][Full Text] [Related]
14. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.
Hensley PJ; Bree KK; Campbell MT; Alhalabi O; Kokorovic A; Miest T; Nogueras-Gonzalez GM; Gao J; Siefker-Radtke AO; Guo CC; Navai N; Dinney CP; Kamat AM
J Urol; 2021 Nov; 206(5):1258-1267. PubMed ID: 34184926
[TBL] [Abstract][Full Text] [Related]
15. Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.
Lee Y; Kim YS; Hong B; Cho YM; Lee JL
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3421-3429. PubMed ID: 33715088
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer: a single Egyptian institution experience.
Abdelrahman I; Aboulkassem H; Elazab A; Abdallah AY; Ismail Y; Taher M
J Egypt Natl Canc Inst; 2023 May; 35(1):13. PubMed ID: 37145329
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for failing to complete gemcitabine-cisplatin neoadjuvant chemotherapy in muscle invasive bladder cancer patients.
Kang H; Suh J; You D; Jeong IG; Hong B; Hong JH; Ahn H; Lim B
Investig Clin Urol; 2024 May; 65(3):256-262. PubMed ID: 38714516
[TBL] [Abstract][Full Text] [Related]
18. Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015.
Nyame YA; Holt SK; Diamontopoulos LN; Winters BR; Psutka SP; Dash A; Schade GR; Lin DW; Yu EY; Grivas P; Gore JL; Wright JL
Urology; 2021 Mar; 149():154-160. PubMed ID: 33373709
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience.
Iyer G; Tully CM; Zabor EC; Bochner BH; Dalbagni G; Herr HW; Donat SM; Russo P; Ostrovnaya I; Regazzi AM; Milowsky MI; Rosenberg JE; Bajorin DF
Clin Genitourin Cancer; 2020 Oct; 18(5):387-394. PubMed ID: 32273235
[TBL] [Abstract][Full Text] [Related]
20. Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study.
Koie T; Ohyama C; Hashimoto Y; Hatakeyama S; Yamamoto H; Yoneyama T; Kamimura N
Int J Clin Oncol; 2013 Aug; 18(4):724-30. PubMed ID: 23011100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
